07-SEP-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3735 255 151 87 38 6 02/06/2019 444 185
Screened at PD     1316 92 66 45 20 4      
Pre-Screened prior to PD     2409 153 75 37 17 2      
Treatment-naive     10 10 10 5 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     512 33 14 7 4 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     1968 235 213 68 29 5      
Screened at PD     1090 106 97 44 22 5      
Pre-Screened prior to PD     813 116 103 19 6 0      
Treatment-naive     10 10 10 5 1 0      
After PD on a Lung_MAP Sub-Study     55 3 3 0 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     191 191 191 58 25 4      
S1900G     32 9 4 2 1 0      
S1900J     13 13 4 1 1 1      
S1900K     22 17 14 7 2 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     531 45 36 25 13 3      
Initial sub-study registrations     519 45 36 25 13 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 21 21 21 19 11 2 05/22/2025 304 95
Docetaxel plus Ramucirumab Y   12 12 12 11 7 2      
Cemiplimab plus Docetaxel and Ramucirumab Y   9 9 9 8 4 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 21 8 4 1 0 0 05/05/2023 285 104
Capmatinib + Osimertinib + Ramucirumab Y   11 5 3 1 0 0      
Capmatinib + Osimertinib Y   10 3 1 0 0 0      
S1900J: MET Amplification: Amivantamab-SC   88 2 2 1 0 0 0 11/19/2024 197 75
Amivantamab SC Y   2 2 1 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 13 12 10 5 2 1 08/08/2024 268 91
Tepotinib + Ramucirumab Y   8 8 6 2 0 0      
Tepotinib Y   5 4 4 3 2 1